131 results on '"Haupt, Axel"'
Search Results
2. Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study
3. Safety and efficacy of once-weekly basal insulin Fc in people with type 2 diabetes previously treated with basal insulin: a multicentre, open-label, randomised, phase 2 study
4. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial
5. Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis with Liver Fibrosis
6. LBO-001 Tirzepatide for the treatment of metabolic dysfunction-associated steatohepatitis with liver fibrosis: results of the SYNERGY-NASH phase 2 trial
7. Effects of Tirzepatide vs Semaglutide on β-cell Function, Insulin Sensitivity, and Glucose Control During a Meal Test
8. Volenrelaxin (LY3540378) increases Renal Plasma Flow: A Randomized Phase 1 Trial
9. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial
10. Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial
11. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial
12. New improved radiometabolite analysis method for [18F]FTHA from human plasma: a test-retest study with postprandial and fasting state.
13. Improvements in post‐challenge lipid response following tirzepatide treatment in patients with type 2 diabetes
14. Improvements in post‐challenge lipid response following tirzepatide treatment in patients with type 2 diabetes.
15. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
16. 52-OR: Effect of Oral Nonpeptide GLP-1 Receptor Agonist Orforglipron (LY3502970) in Participants with Obesity or Overweight—A Phase 2 Study
17. Effects of Tirzepatide Versus Insulin Glargine on Cystatin C-Based Kidney Function: A SURPASS-4 Post-Hoc Analysis
18. Effects of Tirzepatide Versus Insulin Glargine on Cystatin C–Based Kidney Function: A SURPASS-4 Post Hoc Analysis
19. A novel once-weekly Basal Insulin Fc achieved similar glycaemic control with a comparable safety profile versus insulin degludec in patients with type 1 diabetes
20. Tirzepatide Reduces Appetite, Energy Intake and Fat Mass in People with T2D
21. LY3437943 (LY), A Novel Triple GIP/GLP-1/Glucagon Receptor Agonist, Provides Glucose Lowering and Weight Loss in Patients with T2D after 12 Weeks of Treatment
22. Effects of tirzepatide versus insulin glargine 100U/ml on kidney outcomes in people with type 2 diabetes in SURPASS-4
23. Once-weekly Basal Insulin Fc (BIF) demonstrated similar glycaemic control to once-daily Insulin Degludec (IDeg) in insulin-naïve patients with Type 2 Diabetes (T2D)
24. Once Weekly Basal Insulin Fc (BIF) Demonstrated Similar Glycemic Control to Once Daily Insulin Degludec in Insulin-naïve Patients with Type 2 Diabetes, A Phase 2 Randomized Control Trial
25. Once-Weekly Basal Insulin Fc Demonstrated Similar Glycemic Control to Once-Daily Insulin Degludec in Insulin-Naive Patients With Type 2 Diabetes: A Phase 2 Randomized Control Trial
26. Novel Once Weekly Basal Insulin Fc (BIF) Achieved Similar Glycemic Control with A Comparable Safety Profile Versus Insulin Degludec in Patients with Type 1 Diabetes (T1D)
27. Novel Once-Weekly Basal Insulin Fc Achieved Similar Glycemic Control With a Safety Profile Comparable to Insulin Degludec in Patients With Type 1 Diabetes
28. Tirzepatide reduces appetite, energy intake and fat mass in people with T2D
29. Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes
30. Pharmacokinetic and pharmacodynamic properties of the novel basal insulin Fc (insulin efsitora alfa), an insulin fusion protein in development for once‐weekly dosing for the treatment of patients with diabetes
31. Orforglipron (LY3502970), a novel, oral non‐peptide glucagon‐like peptide‐1 receptor agonist: A Phase 1a, blinded, placebo‐controlled, randomized, single‐ and multiple‐ascending‐dose study in healthy participants.
32. The novel GIP, GLP‐1 and glucagon receptor agonist retatrutide delays gastric emptying.
33. Orforglipron (LY3502970), a novel, oral non‐peptide glucagon‐like peptide‐1 receptor agonist: A Phase 1b, multicentre, blinded, placebo‐controlled, randomized, multiple‐ascending‐dose study in people with type 2 diabetes
34. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept
35. 338-OR: Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People with T2D
36. 714-P: Greater Improvement in Insulin Sensitivity Per Unit Weight Loss with Tirzepatide Compared with Selective GLP-1 Receptor Agonism
37. 340-OR: LY3437943 (LY) , a Novel Triple GIP/GLP-1/Glucagon Receptor Agonist, Provides Glucose Lowering and Weight Loss in Patients with T2DM after 12 Weeks of Treatment
38. 17-OR: ADA Presidents' Select Abstract: Effects of Tirzepatide vs. Insulin Glargine 100 U/mL on Kidney Outcomes in Participants with Type 2 Diabetes in SURPASS-4
39. 215-OR: Once Weekly (QW) Basal Insulin Fc (BIF) Demonstrated Similar Glycemic Control to Once Daily (QD) Insulin Degludec (DEG) in Insulin-Naïve Patients with Type 2 Diabetes (T2D)
40. Glycemic Control with Once Weekly Basal Insulin Fc (BIF) in Persons with Type 2 Diabetes Mellitus (T2DM) Using Continuous Glucose Monitoring (CGM) in a Phase 2 Study
41. DUAL GIP-GLP-1 RECEPTOR AGONIST TIRZEPATIDE IMPROVES GLUCOSE CONTROL AND INSULIN SENSITIVITY IN MIXED MEAL TESTS IN PEOPLE WITH TYPE 2 DIABETES
42. Synthesis, Reactivity and Structural Properties of Trifluoromethylphosphoranides
43. Once Weekly (QW) Insulin Efsitora alfa (Efsitora) and Daily Degludec (DEG) Achieve Comparable Glycemic Control in 3 Patient Populations Studied During Phase 2: Clinical Insights from CGM Assessments.
44. Effect of Orforglipron versus Placebo and Dulaglutide on Glycemic Control and Body Weight in Patients with Type 2 Diabetes.
45. Once-weekly Triple Receptor (GIP/GLP-1/Glucagon) Agonist Retatrutide (LY3437943): Efficacy and Safety in a 48-week Obesity Phase 2 Trial.
46. Retatrutide, a triple GIP/GLP-1/glucagon receptor agonist, provides robust HbA1c and body weight reductions to people with type 2 diabetes: a 36--week, phase 2 study.
47. The dual glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 receptor agonist tirzepatide improves cardiovascular risk biomarkers in patients with type 2 diabetes: A p ost hoc analysis
48. Effects of Tirzepatide, a Dual GIP and GLP-1 RA, on Lipid and Metabolite Profiles in Subjects With Type 2 Diabetes
49. Initiation of Once Weekly (QW) Insulin Efsitora alfa (efsitora) in 3 Patient Populations in Phase 2 Studies Using a One-time Loading Dose (LD) Minimizes Transient Hyperglycemia and is not Associated with Excess Hypoglycemia Risk vs Degludec.
50. Effects of Tirzepatide on Eating Behaviour: A Phase 1 Study in People Living with Obesity.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.